<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadlines</th>
</tr>
</thead>
</table>
| Clinical Development Award       | Must be an independent investigator at or above the level of Assistant Professor (or equivalent) | • Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.  
• Near-term impact is expected.  
• Preclinical studies in animals are not allowed.  
• Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.  
• Preliminary data are required.  
• Optional nested Early-Career Investigator: Applications proposing clinical trials and having an Early-Career Investigator that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.  
• NEW: Submission of a Letter of Intent (LOI) is required prior to full application submission. | • Maximum funding of $600,000 for direct costs (plus indirect costs)  
• Maximum funding of $800,000 for direct costs with a qualified nested Early Career Investigator (plus indirect costs).  
• Maximum period of performance is 3 years. | Pre-Application (LOI):  
July 25, 2018  
5:00 p.m. Eastern Time (ET)  
Application:  
August 8, 2018  
11:59 p.m. ET |
| Omics Consortium Development Award | Must be an independent investigator at or above the level of Assistant Professor (or equivalent). | • Supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the origin of ovarian cancer, with a focus on early detection and screening.  
• Funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.  
• Ovarian cancer advocate(s) are required on the research team.  
• Funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in FY20, pending availability of funds.  
• NEW: Submission of a Letter of Intent (LOI) is required prior to full application submission. | • Maximum funding of $400,000 for direct costs (plus indirect costs).  
• Period of performance not to exceed 2 years. | Pre-Application (LOI):  
July 25, 2018  
5:00 p.m. Eastern Time (ET)  
Application:  
August 8, 2018  
11:59 p.m. ET |
# Fiscal Year 2018 Ovarian Cancer Research Program
## Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadlines</th>
</tr>
</thead>
</table>
| Ovarian Cancer Academy Award – Early-Career Investigator | Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.) or equivalent as of the full application submission deadline. A letter attesting to eligibility is required. | - Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.  
- Early-Career Investigators whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.  
- A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.  
- The Designated Mentor is not required to be at the same institution as the Early-Career Investigator.  
- Preliminary data are required.  
- **NEW:** Clinical trials are allowed.  
- **NEW:** Submission of a Letter of Intent (LOI) is required prior to full application submission. | - Maximum funding of $725,000 for direct costs (plus indirect costs)  
- Maximum period of performance is 4 years. | Pre-Application (LOI):  
July 25, 2018  
5:00 p.m. Eastern Time (ET)  
Application:  
August 8, 2018  
11:59 p.m. ET |
# Fiscal Year 2018 Ovarian Cancer Research Program
## Reference Table of Award Mechanisms and Submission Requirements

<table>
<thead>
<tr>
<th>Award Mechanism</th>
<th>Eligibility</th>
<th>Key Mechanism Elements</th>
<th>Funding</th>
<th>Submission Deadlines</th>
</tr>
</thead>
</table>
| Investigator-Initiated Research Award | Must be an independent investigator at or above the level of Assistant Professor (or equivalent) | - Supports meritorious basic and clinically oriented research in ovarian cancer. 
- Impact is an important review criterion. 
- Preliminary data are required. 
- Clinical trials are not allowed. 
- Pre-application is required; application is by invitation only. | - Maximum funding of $450,000 for direct costs (plus indirect costs) 
- Maximum period of performance is 3 years. | Pre-Application: 
May 30, 2018 
5:00 p.m. Eastern Time (ET) 
Invitation to Submit an Application: 
Early July, 2018 
Application: 
August 22, 2018 11:59 p.m. ET |
| Pilot Award                          | Investigators at or above the postdoctoral level (or equivalent).             | - Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward. 
- Innovation and Impact are important review criteria. 
- Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed. 
- Clinical trials are not allowed. 
- Pre-application is required and is blinded; application submission is by invitation only. | - Maximum funding of $250,000 for direct costs (plus indirect costs) 
- Maximum period of performance is 2 years. | Pre-Application: 
May 30, 2018 5:00 p.m. ET 
Invitation to Submit an Application: 
Early July, 2018 
Application: 
August 22, 2018 11:59 p.m. ET |